华人健康 (301408.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

15.9x

Market Cap

CNY 5.96B

MomentumView details →

1D Return

−3.87%

YTD Return

−22.41%

RSI (14)

40.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

15.9x

Market Cap

CNY 5.96B

RSI (14)

40.9

MomentumView details →

1D Return

−3.87%

YTD Return

−22.41%

ProfitabilityView details →

Gross Margin

34.28%

Net Margin

3.71%

EBITDA Margin

6.64%

ROE (TTM)

9.63%

ROA (TTM)

3.77%

Asset Turnover

1.02x

GrowthView details →

Revenue YoY

+20.17%

EPS YoY

+39.01%

FCF YoY

+3.19%

Revenue CAGR 3Y

+18.92%

EPS CAGR 3Y

+0.70%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.42x

Current Ratio

1.13x

Quick Ratio

0.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

5.64B

Net Income (TTM)

209.47M

Op. CF (TTM)

778.41M

Latest newsMore news →

Huaren Health's subsidiary Jiangsu Shenhua Pharmaceutical received a drug registration certificate for Sacubitril Valsartan Sodium Tablets (100mg) from the National Medical Products Administration.50d ago

Similar companies

润欣科技300493.SZ 红旗连锁002697.SZ 信邦制药002390.SZ 华凯易佰300592.SZ 盈方微000670.SZ 东方中科002819.SZ

Latest newsMore news →

Huaren Health's subsidiary Jiangsu Shenhua Pharmaceutical received a drug registration certificate for Sacubitril Valsartan Sodium Tablets (100mg) from the National Medical Products Administration.50d ago